89.36 0.00 (0.00%)
After hours: 4:29PM EDT
|Bid||83.00 x 1200|
|Ask||89.56 x 1100|
|Day's Range||88.25 - 89.86|
|52 Week Range||45.96 - 92.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||95.57|
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios ...
–Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations–. –New Data From Fully Enrolled ...
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
The Cambridge, Massachusetts-based company said it had a loss of $1.63 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
–Commercial Infrastructure In Place Ahead of August 21, 2018 PDUFA Action Date for TIBSOVO ® for IDH1m R/R AML–. –Clinical Portfolio Advancing with Four Compounds in Development and Five Pivotal Trials ...
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
CAMBRIDGE, Mass., April 27, 2018-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations ...
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
CAMBRIDGE, Mass., April 11, 2018-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations ...
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
Agios Pharmaceuticals (AGIO) is a biopharmaceutical company with therapeutic focus areas of cancer and rare genetic diseases. Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one analyst gave it a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Stock Monitor: Albireo Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Agios Pharma, Inc. (NASDAQ: AGIO ). If ...